CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 100.3% in May

CNS Pharmaceuticals, Inc. (NASDAQ:CNSPGet Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 62,500 shares, an increase of 100.3% from the April 30th total of 31,200 shares. Based on an average trading volume of 354,100 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the company’s shares are short sold.

CNS Pharmaceuticals Trading Up 3.0 %

Shares of NASDAQ:CNSP opened at $0.22 on Friday. CNS Pharmaceuticals has a 12 month low of $0.19 and a 12 month high of $2.98. The company has a 50-day moving average price of $0.24 and a 200 day moving average price of $0.74. The company has a market cap of $2.58 million, a price-to-earnings ratio of -0.06 and a beta of 2.78.

CNS Pharmaceuticals (NASDAQ:CNSPGet Free Report) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.95) earnings per share (EPS) for the quarter.

Institutional Trading of CNS Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CNSP. Armistice Capital LLC purchased a new position in CNS Pharmaceuticals during the fourth quarter valued at approximately $155,000. Virtu Financial LLC grew its holdings in CNS Pharmaceuticals by 616.6% in the first quarter. Virtu Financial LLC now owns 94,246 shares of the company’s stock worth $34,000 after purchasing an additional 81,094 shares during the last quarter. Finally, Smith Anglin Financial LLC purchased a new position in CNS Pharmaceuticals in the fourth quarter worth $64,000. Institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

(Get Free Report)

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.

Recommended Stories

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with's FREE daily email newsletter.